Market Place
Sourcing Support
Kyowa Kirin Announces Leadership Changes to Strengthen Operations
31 Oct 2024 //
BUSINESSWIRE
Kyowa Kirin Strengthens Leadership for Global Operations
31 Oct 2024 //
PR NEWSWIRE
Kyowa Kirin Announces Positive Data For Mogamulizumab At EORTC 2024
08 Oct 2024 //
BUSINESSWIRE
Orchard And Er-Kim Partner For Libmeldy Access In Turkey
07 Oct 2024 //
GLOBENEWSWIRE
Kyowa Kirin Announces Positive Data For Mogamulizumab In Lymphoma
07 Oct 2024 //
BUSINESSWIRE
Kyowa Kirin Presents Real-World Evidence Of Burosumab treatment
30 Sep 2024 //
BUSINESSWIRE
Kyowa Kirin Announces Rocatinlimab Phase 3 Top-line Data
25 Sep 2024 //
PR NEWSWIRE
Kyowa Kirin To Present XLH Research At ASBMR Meeting
19 Sep 2024 //
PR NEWSWIRE
New Analysis Shows Work Impact Of X-linked Hypophosphataemia
10 Sep 2024 //
BUSINESSWIRE
Orchard Therapeutics Announces Presentations At SSIEM 2024
28 Aug 2024 //
GLOBENEWSWIRE
Kyowa Kirin pulls decades-old breast cancer drug Fareston from US market
26 Aug 2024 //
FIERCE PHARMA
Kyowa Kirin to end distribution of Fareston (toremefine) in the United States
23 Aug 2024 //
PR NEWSWIRE
Kyowa Kirin, NewBridge To Improve Rare Disease Medicine Access In MENA
08 Aug 2024 //
BIOSPECTRUM ASIA
Kyowa Kirin And NewBridge Partner For Rare Disease Medicines In MENA
07 Aug 2024 //
BUSINESSWIRE
DKSH and Kyowa Kirin Forge Strategic Partnership Across Asia-Pacific
02 Aug 2024 //
PRESS RELEASE
Kyowa Kirin Cuts Research And Manufacturing Jobs, Slims Asian Ops
01 Aug 2024 //
FIERCE PHARMA
NICE Enables Access to First Treatment for XLH in Adults
21 Jun 2024 //
BUSINESSWIRE
Kyowa Kirin to build $530M biologics plant in North Carolina
11 Jun 2024 //
FIERCE PHARMA
Kyowa Kirin Approves New Biologics Plant In Sanford, NC
10 Jun 2024 //
PR NEWSWIRE
UK biotech revives former Kyowa Kirin cancer drug Epstein-Barr-driven diseases
23 May 2024 //
ENDPTS
Kyowa Kirin: Pre-Clinical Data Presentation at ARVO Annual Meeting 2024
08 May 2024 //
PR NEWSWIRE
Orchard`s Gaspar Named To Inaugural TIME100 Health List
03 May 2024 //
GLOBENEWSWIRE
Kyowa Announces Acceptance of Abstract for Presentation at the Annual Meeting
02 Apr 2024 //
PR NEWSWIRE
Kyowa`s Orchard hopes $4.25M gene therapy price tag bears fruit
20 Mar 2024 //
FIERCE PHARMA
Kyowa Kirin plots $200M plant in NC, where it`ll hire 100-plus
01 Mar 2024 //
FIERCE PHARMA
Kyowa Kirin Announce Symposium, Acceptance of Abstract for Presentation
14 Feb 2024 //
PR NEWSWIRE
Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Evaluating Tivozanib
06 Feb 2024 //
PR NEWSWIRE
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics
24 Jan 2024 //
GLOBENEWSWIRE
Boehringer ends week with 3rd deal, this time with Kyowa Kirin
06 Jan 2024 //
PRESS RELEASE
Hoc Analysis from MAVORIC Trial Sheds Light on Burden of T-Cell Lymphoma
11 Dec 2023 //
BUSINESSWIRE
Kyowa Kirin Responds to NICE’s Publication of Appraisal Document for CRYSVITA
29 Nov 2023 //
BUSINESSWIRE
Kyowa Kirin Presents Real-World Findings at ASBMR Annual Meeting
16 Oct 2023 //
PR NEWSWIRE
Kyowa Kirin to Present New Research on XLH at ASBMR Annual Meeting
12 Oct 2023 //
PR NEWSWIRE
Kyowa Kirin Buys Orchard for Potential $478M as FDA Decision Looms
06 Oct 2023 //
BIOSPACE
Kyowa Kirin Announces Acceptance for Presentations at Congress 2023
04 Oct 2023 //
PR NEWSWIRE
Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO
21 Sep 2023 //
BUSINESSWIRE
Grünenthal, Kyowa Kirin International Enter Joint Venture Collaboration
02 Aug 2023 //
PR NEWSWIRE
Kyowa Kirin Designs New North American Headquarters to Accelerate Innovation
11 Jul 2023 //
PR NEWSWIRE
Kyowa renews support for foundation that fulfills wishes for terminally ill
01 Jun 2023 //
ENDPTS
Kyowa Kirin Presents New Findings from Real-World Study in Parkinson`s Disease
12 May 2023 //
PR NEWSWIRE
Reata culls bardoxolone, ending decade of R&D on troubled kidney disease drug
11 May 2023 //
ENDPTS
Reata, Kyowa Kirin ax bardoxolone, ending 13-year saga
10 May 2023 //
FIERCE BIOTECH
Kyowa Kirin brings rare disease drug`s marketing back in house, future US growth
03 May 2023 //
ENDPTS
Kyowa Kirin North America Assumes Commercial Leadership Role for CRYSVITA
27 Apr 2023 //
PR NEWSWIRE
Kyowa Kirin Appoints Pharma Industry Leader Steve Schaefer as President
11 Apr 2023 //
PR NEWSWIRE
Kyowa Kirin Will Present New Rocatinlimab Phase 2b Data in Atopic Dermatitis
17 Mar 2023 //
PR NEWSWIRE
Kyowa Kirin Announces Acceptance for Presentation at Annual Meeting 2023
07 Mar 2023 //
PR NEWSWIRE
MEI and Kyowa Kirin to discontinue development of zandelisib outside Japan
07 Dec 2022 //
PHARMACEUTICAL-TECHNOLOGY
FDA feedback drives MEI, Kyowa to halt blood cancer program
06 Dec 2022 //
FIERCEBIOTECH
MEI Pharma & Kyowa Kirin Announce Discontinuation of Zandelisib Outside of Japan
06 Dec 2022 //
BUSINESSWIRE
Kyowa Kirin offloads mature drugs to Grünenthal in Europe
28 Nov 2022 //
FIERCEPHARMA
Grunenthal and Kyowa Announce Collaboration for Established Medicines Portfolio
25 Nov 2022 //
BUSINESSWIRE
Kyowa Kirin and MEI Pharma report data from Phase II lymphoma trial
21 Nov 2022 //
CLINICALTRIALSARENA
MEI, Kyowa confirm phase 2 cancer efficacy with fresh data drop
19 Nov 2022 //
FIERCEPHARMA
Ardelyx & Kyowa, Announces Submission of NDA for Tenapanor for Hyperphosphatemia
31 Oct 2022 //
PRNEWSWIRE
Grünenthal Is Said to Lead Race for Kyowa Kirin International
14 Oct 2022 //
FIRSTWORLDPHARMA
Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA
19 Aug 2022 //
BUSINESSWIRE
Amgen hits pause on $400M eczema bet to tweak phase 3 study
05 Aug 2022 //
FIERCEBIOTECH
Amarin suspends German sales force as Vascepa`s European launch sputters
05 Aug 2022 //
FIERCEPHARMA
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology
18 Jul 2022 //
BUSINESSWIRE
